Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
Key facts
- Study ID
- NCT00003176
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 82
- Starts
- 1998-03-25
- Expected to finish
- 2004-01-06
- Last updated by the study team
- 2018-06-27
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
- UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
- Simmons Cancer Center - Dallas — Dallas, Texas, United States
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.